<DOC>
	<DOCNO>NCT01621425</DOCNO>
	<brief_summary>Docetaxel use first line anti-cancer drug treatment several cancer , mainly breast- metastatic castration-resistant prostate carcinoma . Anti-cancer drug dose base patient estimate Body Surface Area order equalize total drug exposure . Nevertheless , docetaxel treatment characterize highly interindividual pharmacokinetic variation lead toxicity under-treatment . The investigator determine anthropometric parameter , LBM , total body weight ( TBW ) BSA correlate best docetaxel exposure ( AUC ) males female .</brief_summary>
	<brief_title>Lean Body Mass Determinant Docetaxel Pharmacokinetics Toxicity</brief_title>
	<detailed_description>Docetaxel use first line anti-cancer drug treatment several cancer , mainly breast- metastatic castration-resistant prostate carcinoma . Anti-cancer drug dose base patient estimate Body Surface Area order equalize total drug exposure . Nevertheless , docetaxel treatment characterize highly interindividual pharmacokinetic variation lead toxicity under-treatment . For anti-cancer drug , include docetaxel , anthropometric parameter , Lean Body Mass ( LBM ) , suggest superior Body Surface Are ( BSA ) determinant dose implemented clinical practice . The investigator determine anthropometric parameter , LBM , total body weight ( TBW ) BSA correlate best docetaxel exposure ( AUC ) males female . The investigator determine occurrence docetaxel toxicity relate dose/LBM . The investigator determine method measure LBM : DEXA , Bioelectrical Impedance Assessments ( BIA ) formula estimate accurate enough dosing calculation use dose docetaxel .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Subject least 18 Subject able willing sign Informed Consent Form prior screen evaluation Female subject diagnose breast carcinoma receive docetaxel treatment accord standard hospital protocol ( TAC regimen ) male subject diagnose metastatic castrationresistant prostate carcinoma receive docetaxel treatment accord standard hospital protocol ( PRODOC regimen ) Subject live expectancy 12 week great Absolute neutrophile count ( ANC ) &gt; 1.5 x 10E9/L Platelet count &gt; 100 x 10E9/L Serum creatinine ≤ 2 x ULN Total bilirubin level &lt; 1.5 x ULN Docetaxel treatment within last year Moderate severe liver impairment ; [ ALAT and/or ASAT ≥ 1.5 ULN ] [ AF ≥ 2.5 ULN ] Current therapy drug , dietary supplement , compound , use last 2 week prior first docetaxel administration , know inhibit induce CYP3A4 . Inability understand nature extent study procedure require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>prostate carcinoma</keyword>
	<keyword>docetaxel</keyword>
	<keyword>lean body mass</keyword>
	<keyword>Body Surface Area</keyword>
	<keyword>body weight</keyword>
	<keyword>dexascan</keyword>
</DOC>